Drug Trial Radar · NCT01120028
Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy
Last checked: Nov 20, 2026Latest source record: Apr 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
852
Actual
Start
Sep 2010
Primary completion
Feb 2014
Study completion Mar 2020
Sponsor
- Lead sponsor
- University of OxfordAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Health Service, United Kingdom; Pfizer; Novartis
- First posted
- May 10, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The 3C study is investigating whether reducing exposure to calcineurin inhibitors (by using more potent antibody induction treatment and/or an elective switch to sirolimus) can improve the function and survival of kidney transplants.
Conditions
- Kidney Transplantation
Interventions
AlemtuzumabDrug
Alemtuzumab 30 mg intravenously or subcutaneously, two doses 24 hours apart
BasiliximabDrug
20 mg intravenously, two doses 96 hours apart
SirolimusDrug
Sirolimus: target trough levels 6-12 ng/mL for first 6-months after maintenance therapy randomization, then 5-10 ng/mL
TacrolimusDrug
Tacrolimus: target trough levels 5-7 ng/mL after maintenance therapy randomization.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Biopsy-proven Acute Rejection at 6-months After Randomization to Induction TherapyTime frame: 6 months post-transplantation
- Graft Function (at 18-months After Randomization to Maintenance Therapy)Time frame: 2 years post-transplantation
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom
Addenbrooke's Hospital NHS Trust
Cambridge, United Kingdom
University Hospital of Wales
Cardiff, United Kingdom
University Hospitals Coventry & Warwickshire
Coventry, United Kingdom
Royal Infirmary
Edinburgh, United Kingdom
Western Infirmary
Glasgow, United Kingdom
Hull and East Yorkshire Hospitals NHS Trust
Hull, United Kingdom
Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom
Royal Liverpool and Broadgreen University Hospitals NHS Trust
Liverpool, United Kingdom
Bart's and the London NHS Trust
London, United Kingdom
Guy's and St Thomas's NHS Trust
London, United Kingdom
Kings College Hospital NHS Trust
London, United Kingdom
Royal Free Hampstead NHS Trust
London, United Kingdom
Central Manchester NHS Trust
Manchester, United Kingdom
Newcastle-upon-Tyne Hospitals NHS Trust
Newcastle, United Kingdom
Nottingham University Hospitals NHS Trust
Nottingham, United Kingdom
Plymouth Teaching Hospitals NHS Trust
Plymouth, United Kingdom
Portsmouth Hospitals NHS Trust
Portsmouth, United Kingdom
Sheffield Teaching Hospitals NHS Trust
Sheffield, United Kingdom
Oxford Radcliffe Hospitals NHS Trust
Oxford, Oxon, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.